A multicenter randomized controlled trial of intrapleural perfusion of methotrexate‐loaded tumor cell‐derived microparticles combined with systemic therapy for malignant pleural effusion
International Journal of Cancer · 01.01.2026 · 158 (1) · 172-181
DOI: 10.1002/ijc.70094 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Cancer, online erschienen am 16.08.2025. Verfasst von Cheng Zeng und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Methotrexate, Pleural Effusion, Malignant, Cell-Derived Microparticles, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, Joint innovative Fund of Beijing Natural Science Foundation and Changping District.
Abstract (Originalsprache)
This study evaluated the efficacy and safety of intrapleural perfusion with methotrexate‐loaded tumor cell‐derived microparticles (MTX‐TMPs) combined with systemic therapy (ST) in patients with malignant pleural effusion (MPE) secondary to lung or breast cancer. In this multicenter, randomized, open‐label trial, 102 patients were assigned 1:1 to receive either MTX‐TMPs intrapleural perfusion (50 mL daily for 4 days) plus ST (cohort 1) or interleukin‐2 (IL‐2) intrapleural perfusion (50 mL every 3 days for three sessions) plus ST (cohort 2). The objective response rate (ORR) and disease control rate (DCR) of pleural effusion were evaluated in 91 patients (50 in cohort 1, 41 in cohort 2). ORR was significantly higher in cohort 1 than in cohort 2 (76.0% vs. 53.7%, p = 0.025), as was DCR (92.0% vs. 70.7%, p = 0.012). Among 83 patients included in the survival analysis, the median overall survival (OS) was 15.0 months (95% CI: 9.2–26.9) in cohort 1 and 6.9 months (95% CI: 5.3–15.8) in cohort 2 (HR = 0.75; 95% CI: 0.46–1.24; p = 0.266). One‐, two‐, and three‐year OS rates in cohort 1 were 55.3%, 36.2%, and 25.5%, compared to 38.9%, 25.0%, and 25.0% in cohort 2. Both regimens showed manageable safety profiles, with anemia, pyrexia, fatigue, leukopenia, gastrointestinal symptoms, and liver dysfunction being the most common treatment‐related adverse events. These findings suggest that intrapleural perfusion of MTX‐TMPs combined with ST represents a promising and safe strategy for the management of MPE in patients with lung or breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Internal Oncology, Anyang City Cancer Hospital, Anyang, Henan Province, China.
- Department of Thoracic Oncology, Hubei Province Cancer Hospital, Wuhan, Hubei Province, China.
- Department of Oncology, Second People's Hospital of Hunan Province, Changsha, Hunan Province, China.
- Department of Oncology, Anhui Province Thoracic Hospital, Hefei, Anhui Province, China.
- Department of Oncology, Xiangyang City Central Hospital, Xiangyang, Hubei Province, China.
ORCID-Profile: Cheng Zeng, Yujing Tan, Fei Ma
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National Natural Science Foundation of China
- Joint innovative Fund of Beijing Natural Science Foundation and Changping District
- Special Research Fund for Central Universities, Peking Union Medical College
- CAMS Innovation Fund for Medical Sciences (CIFMS)
Zitieren
APA
Zeng, C., Tan, Y., Jiao, Z., Hu, S., Tang, S., Shi, Q., Yi, T., Chen, J., Cai, M., Liu, H., Liu, X., Zhu, J., Sun, P., Zhang, Y., Zhu, T., Jin, H., Wang, Z., Zhang, M., Yu, G., …, & Ma, F. (2026). A multicenter randomized controlled trial of intrapleural perfusion of methotrexate‐loaded tumor cell‐derived microparticles combined with systemic therapy for malignant pleural effusion. International Journal of Cancer, 158(1), 172-181. https://doi.org/10.1002/ijc.70094
Vancouver
Zeng C, Tan Y, Jiao Z, Hu S, Tang S, Shi Q, et al. A multicenter randomized controlled trial of intrapleural perfusion of methotrexate‐loaded tumor cell‐derived microparticles combined with systemic therapy for malignant pleural effusion. International Journal of Cancer. 2026;158(1):172-181. doi:10.1002/ijc.70094
BibTeX
@article{Zeng2026,
author = {Zeng, Cheng and Tan, Yujing and Jiao, Zhimin and Hu, Sheng and Tang, Sanyuan and Shi, Qingming and Yi, Tienan and Chen, Jiming and Cai, Mei and Liu, Hu and Liu, Xinyan and Zhu, Jingyan and Sun, Ping and Zhang, Yan and Zhu, Ting and Jin, Hongyan and Wang, Zhiyu and Zhang, Mengxian and Yu, Guohua and Wang, Jiani and Ma, Fei},
title = {A multicenter randomized controlled trial of intrapleural perfusion of methotrexate‐loaded tumor cell‐derived microparticles combined with systemic therapy for malignant pleural effusion},
journal = {International Journal of Cancer},
year = {2026},
volume = {158},
number = {1},
pages = {172--181},
doi = {10.1002/ijc.70094}
}
EUVIMED